← Leaderboards
Peter George Pappas
University Of Alabama At Birmingham
$6,523,821
Attributed
$6,523,821
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$5,356,697 · 3
NIH$1,167,124 · 7
By mechanism
U01$5,356,697 · 3
M01$944,374 · 6
R34$222,750 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- John Franklin Kearney$21,145,276
- Kent Avery Willis$854,280
- Casey T Weaver$23,846,284
- Polly Roy$6,105,431
- Robert Floyd Pass$10,874,670
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationMycosisAmphotericin BAntifungal AgentsMicroorganism Disease ChemotherapyLymphatic DisorderItraconazoleHistoplasmosisIntravenous AdministrationBlastomycosisFungiMicroorganism Resource /RegistryMycosesLongitudinal Human StudyIncidenceGenetic PolymorphismInstitutionDoseDisease /Disorder Prevention /ControlData Collection Methodology /EvaluationPersons
Grant awards (22)
RFA-CK-23-001, Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases$1,499,900
U01 · FY2025 · CK · contact PI
RFA-CK-23-001, Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases$1,499,999
U01 · FY2024 · CK · contact PI
RFA-CK-23-001, Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases$1,498,723
U01 · FY2023 · CK · contact PI
A randomized, sequential dose escalation study comparing open-label T2307 to standard of care in candidemia due to Candida auris or other drug-resistant Candida species: A phase 2/3 adaptive design$222,750
R34 · FY2020 · AI · contact PI
Transplant Associated Infection Surveillance Network Phase II$1,000
U01 · FY2012 · CK · contact PI
Transplant Associated Infection Surveillance Network Phase II$60,000
U01 · FY2011 · CK · contact PI
Transplant Associated Infection Surveillance Network Phase II$130,000
U01 · FY2010 · CK · contact PI
Transplant Associated Infection Surveillance Network$200,000
U01 · FY2008 · CI · contact PI
Transplant Associated Infection Surveillance Network$200,000
U01 · FY2007 · CI · contact PI
BAMSG 3-01$89,619
M01 · FY2007 · RR · contact PI
Transplant Associated Infection Surveillance Network$267,075
U01 · FY2006 · CI · contact PI
BAMSG 3-01$65,144
M01 · FY2006 · RR · contact PI
Transplant Associated Infection Surveillance Network$0
U01 · FY2005 · CI
Transplant Associated Infection Surveillance Network$0
U01 · FY2004 · CI
LAMISIL IN CUTANEOUS OR LYMPHOCUTANEOUS SPOROTRICHOSIS$175,256
M01 · FY2002 · RR
IV ITRACONAZOLE VS AMPHOTERICIN B IN BLASTOMYCOSIS OR HISTOPLASMOSIS$175,256
M01 · FY2002 · RR
IV ITRACONAZOLE VS AMPHOTERICIN B IN BLASTOMYCOSIS OR HISTOPLASMOSIS$175,256
M01 · FY2001 · RR
LAMISIL IN CUTANEOUS OR LYMPHOCUTANEOUS SPOROTRICHOSIS$175,256
M01 · FY2001 · RR
IV ITRACONAZOLE VS AMPHOTERICIN B IN BLASTOMYCOSIS OR HISTOPLASMOSIS$29,529
M01 · FY2000 · RR
NATURAL HISTORY OF GENITAL HUMAN PAPILLOMAVIRUS IN RENAL TRANSPLANTS$29,529
M01 · FY2000 · RR
LAMISIL IN CUTANEOUS OR LYMPHOCUTANEOUS SPOROTRICHOSIS$29,529
M01 · FY2000 · RR
POLYMORPHISMS IN RISK FOR BLASTOMYCES DERMATITIDES$0
M01 · FY2000 · RR